Literature DB >> 21669370

The use of quality-adjusted life-years in the economic evaluation of health technologies in Spain: a review of the 1990-2009 literature.

José Manuel Rodriguez1, Silvia Paz, Luis Lizan, Paloma Gonzalez.   

Abstract

OBJECTIVE: To appraise economic evaluations of health technologies that included quality-adjusted life-years (QALYs) as an outcome measure conducted over the past 20 years in Spain.
METHODS: A systematic review of the literature was conducted. Economic evaluations that included QALYs as an outcome measure, conducted in Spain and published between January 1990 and December 2009 were identified. Primary and gray literature sources were reviewed.
RESULTS: A total of 60 articles and 4 health technology assessment reports were included. Key findings were 1) the vast majority of articles (77.1%) referred to therapeutic interventions; 2) 63.2% dealt with pharmaceutical products and much fewer with preventive strategies, medical devices, or diagnostic interventions; 3) most evaluations referred to cardiovascular- (19.8%), respiratory- (16.3%), and cancer- (13.0%) related processes; 4) 80.3% were based on a theoretical model, most commonly Markov models (71.4%); 5) 67.3% adopted the National Health System perspective; 6) information on the methods used to describe the health states was given in 45.1% of studies; 7) 40.3% used the EuroQoL-5D to elicit preferences, whereas 66.1% gave no details on the methods applied to determine patients' choices; 8) it was possible to state who completed the questionnaires in only 17.7% of studies; 9) 77.1% of the interventions assessed were below the €30,000/QALY suggested affordable threshold in Spain.
CONCLUSIONS: An increasing number of economic evaluations using QALYs had been conducted. Most of them relied on theoretical models. Several methodological issues remain unsolved. Great disparity exists regarding the reporting of the methods used to determine health states and utility values.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21669370     DOI: 10.1016/j.jval.2010.10.039

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  6 in total

Review 1.  The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications.

Authors:  José Manuel Rodríguez Barrios; Ferran Pérez Alcántara; Carlos Crespo Palomo; Paloma González García; Enrique Antón De Las Heras; Max Brosa Riestra
Journal:  Eur J Health Econ       Date:  2011-06-10

2.  Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.

Authors:  Pedro Mezquita-Raya; Antonio Ramírez de Arellano; Nana Kragh; Gabriela Vega-Hernandez; Johannes Pöhlmann; William J Valentine; Barnaby Hunt
Journal:  Diabetes Ther       Date:  2017-02-21       Impact factor: 2.945

3.  Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain.

Authors:  Parastu Kasaie; Matthew Radford; Sunaina Kapoor; Younghee Jung; Beatriz Hernandez Novoa; David Dowdy; Maunank Shah
Journal:  PLoS One       Date:  2018-11-05       Impact factor: 3.240

Review 4.  The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review.

Authors:  Ferrán Catalá-López; Manuel Ridao; Adolfo Alonso-Arroyo; Anna García-Altés; Chris Cameron; Diana González-Bermejo; Rafael Aleixandre-Benavent; Enrique Bernal-Delgado; Salvador Peiró; Rafael Tabarés-Seisdedos; Brian Hutton
Journal:  Syst Rev       Date:  2016-01-07

5.  Health Economic Evaluations of Cancer in Brazil: A Systematic Review.

Authors:  Alessandro G Campolina; Tania Y Yuba; Tassia C Decimoni; Roseli Leandro; Maria Del Pilar Estevez Diz; Hillegonda M D Novaes; Patrícia C de Soárez
Journal:  Front Public Health       Date:  2018-07-27

Review 6.  Understanding the global measurement of willingness to pay in health.

Authors:  Jean A McDougall; Wesley E Furnback; Bruce C M Wang; Jörg Mahlich
Journal:  J Mark Access Health Policy       Date:  2020-02-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.